flag flag  

Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.

Description : On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) conc...
Language(s) : English
Subject(s) : Aged , Erythropoietin, Recombinant/therapeutic use , Female , Hematologic Diseases/blood/surgery , Humans , Male , Middle Aged , Peripheral Blood Stem Cell Transplantation/methods , Transplantation, Autologous , Human health sciences :: Hematology [D11] , Sciences de la santé humaine :: Hématologie [D11]
Publisher(s) :
Contributor(s) :
Source(s) : &ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&jtitle=Haematologica&issn=0390-6078&eissn=1592-8721&volume=90&issue=9&pages=1269-70&pub=Ferrata+Storti+Foundation&place=Pavia&place=Italy
Publication Date(s) : 2005-01-01